BREXIT – Impact on Medical Devices placed in the UK market
From 31 of December 2020, the UK will be regarded as a third country and not a Member State of the European Union. There will be some changes regarding medical devices placed in the UK. The UK’s MHRA has published guidance regarding the regulation of medical devices from 1 January 2021, where it explains what changes and what there is to know about placing a medical device in the Great Britain, Northern Ireland and EU markets.


After 31 of December 2020 (end of the so-called ‘transition period’), the United Kingdom (UK) will be considered a third country and not a Member State of the European Union, meaning that all EU rules and regulations will no longer be applied to medical devices placed in the UK market. After the transition period, the rules for Northern Ireland will be different from those in Great Britain, as EU rules will continue to apply in this country (e.g. CE marking, EU-based manufacturer or Authorized Representative).

At the moment, medical devices are regulated under Directive 90/385/EEC (on active implantable medical devices – EU AIMDD), Directive 93/42/EEC (on medical devices – EU MDD) and Directive 98/79/EC (on in vitro diagnostic medical devices – EU IVDD), which are given effect in the UK law through the Medical Devices Regulations 2002 (SI 2002 No 618, as amended) (UK MDR 2002). These Regulations (in the form in which they will exist on January 1st 2021) will continue to have effect in Great Britain after the transition period.

In 2017, two Regulations on medical devices and in in vitro diagnostic medical devices entered into force in the European Union (EU) and started to replace the three existing Directives, establishing a modernized and more robust EU legislative framework and safeguarding a better public health protection and patient safety. The EU Medical Devices Regulation (MDR – Regulation (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR – Regulation (EU) 2017/746) will fully apply from 26 May 2021 and 26 May 2022, respectively. As these regulations will not take effect until after the transition period with the EU has ended, they will not be EU law automatically retained by the EU Withdrawal Agreement Act and will therefore not automatically apply in Great Britain.

After the transition period, medical devices manufactured in the United Kingdom and placed on the EU market will be regarded as products imported form a third country. In this sense, manufacturers from the UK will need an Authorized Representative and importer located in the European Union. On the other hand, if a manufacture is based outside the UK and wishes to place a medical device on the UK market, it will need to establish an UK Responsible person, who will take the responsibility for the device in this country.


For medical devices placed in Great Britain, there will be some changes, beginning on January 1st 2021.  From this date, the Medicines and Healthcare products Regulatory Agency (MHRA) will be the sole authority responsible for medical devices marketed in the UK. MHRA is the designated competent authority that administers and enforces law on medical devices in the UK.

  • CE Certificates issued by European Economic Area (EEA)-based Notified Bodies will continue to be valid for the Great Britain market until June 30th, 2023.
  • A new route to market and product marking will be available for manufacturers wishing to place a device on the Great Britain market from January 1st 2021.
  • From January 1st 2021, all medical devices and in vitro diagnostic medical devices placed on the UK market will need to be registered with the MHRA. Grace periods will be granted for the registration:
    • 4 months for Class IIIs and Class IIb implantables, and all active implantable medical devices.
    • 8 months for other Class IIb and all Class IIa devices.
    • 12 months for Class I devices (do not apply to manufacturers of Class I devices and general IVDs that are currently required to register with the MHRA).
  • The need for an UK Responsible Person if the manufacture is based outside this country and this manufacture will first need to register with the MHRA.

From 1st January 2021, all medical devices, IVD or custom-made devices need to be registered with MHRA, before being placed on the UK market.

Notified Bodies on the UK will no longer be able to issue CE Mark certificates. The UK Conformity Assessed (UKCA) mark is a new UK product marking that will be applied to medical devices (and other products) being placed in the UK after the transition period. From 1st July 2023, the medical device being marketed in the UK will need to fulfil the requirements for placing the UKCA mark. This UKCA mark will not be recognized in the EU, EEA or Northern Ireland markets and products which are required to have a CE marking will continue to have this requirement to be sold in these markets.

Finally, manufacturers will be required to submit vigilance reports to the MHRA if the medical device is placed in the UK when certain incidents with their device occur in this country.  


  1. Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, 19 October 2019. Available at:
  2. Medicines and Healthcare products Regulatory Agency (MHRA) – Guidance – Regulating medical devices from 1 January 2021. Available at:
  3. Medicines and Healthcare products Regulatory Agency (MHRA) – Medical devices: the regulations and how we enforce them. Available at:


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »